CBDepotis one of Europe’s leading licensed suppliers of isolated and synthesized cannabinoids and cannabidiol-enriched products for the industrial and B2B markets.

We develop and produce high quality cannabinoids used in the food, cosmetics and pharmaceutical industries. Our products also are used in clinical trials.


All CBDepot products go through a rigorous process that renders them “tracked, tested and trusted,” based on highly disciplined internal controls which meet Good Manufacturing Practices (GMP) certification requirements. Our quality standards are underscored by our affiliation with scientists and researchers at the Prague Institute of Chemical Process Fundamentals (ICPF), a part of the Czech Academy of Sciences. Our products contain undetectable levels of THC.

Follow us

The products in our portfolio include:

(-)-trans-Cannabidiol, isolated (CBD >98%), derivative of industrial hemp (Cannabis sativa L.) for professional use in e-liquids, and skin-care products with properties as an antioxidant and antiseborrhoeic, and for skin conditioning and protection.

Cannabigerol, isolated (CBG >95%), industrial raw material for professional use only. A derivative of industrial hemp (cannabis sativa L)

Hemp Flavouring Preparation (THC-free). Made from edible parts of hemp plant (Cannabis sativa L.) Contains naturally present phytocannabinoids (50g Cannabidiol or 50g Cannabigerol /100g of product), terpens and waxes. Flavoring preparation as per EC/ 1334/2008, Art. 3.2(d)(i)

(-)-trans-Cannabidiol, GMP (Cannabidiolum) this product is manufactured, handled and stored in accordance with Good Manufacturing Practice (GMP) and as outlined un the International Conference on Harmonization “ICH Q7 guideline on Good Manufacturing Practice for Active Pharmaceutical Ingredients”.

(+/-)-Cannabichromene,

synthesized and (-)- trans-Cannabidiol, synthesized

Bulk and white label, for customers who want to package their own end-user products, we offer custom-made bulk and white label formulationsthrough our joint venture with Cannabis Pharma s.r.o, which has been processing hemp for use in medicinal hemp cosmetics since 2002.

(-)-trans-Cannabidiol, GMP (Cannabidiolum), substance of choice, public tender winner in 2017 and 2019 for paediatric hospital and Institute of Oncology in Ljubljana.

Go to article: Home | The power of patientsGo to article: Scandinavian Health Company InsightGo to article: Scandinavian Health Ltd.Go to article: In this issueGo to article: NSFGo to article: ContentsGo to article: CapsugelGo to article: Capsugel Company Insight Go to article: Christensella: the key to unlocking gut microbiome-based drug discovery?Go to article: Molnar Company InsightGo to article: Molnar-InstituteGo to article: A costly oversight: the ongoing impact of the valsartan recallGo to article: Novo Nordisk Company InsightGo to article: Novo NordiskGo to article: Where is the UK’s supply of Migraleve?Go to article: Dupont PharmaceuticalsGo to article: Discussing drug policy reform with psychedelics campaigner Amanda FeildingGo to article: LB Bohle Company Insight Go to article: LB BohleGo to article: Charting the life and times of the EMA as it leaves LondonGo to article: Komtur Pharmaceuticals Company InsightGo to article: Komtur PharmaceuticalsGo to article: CBD: the myth, the magic and the real deal drugsGo to article: CBDepot Company InsightGo to article: CBDepotGo to article: In the age of AMR, does a nationalised drug company make sense? The case for and againstGo to article: AtoZ-CRO Company InsightGo to article: AtoZ-CROGo to article: How do cancer cells communicate and can it help us catch them?Go to article: HOF SonderanlagenbauGo to article: HOF Sonderanlagenbau Company Insight Go to article: Buyers’ clubs: the first step toward universal UK access to Orkambi?Go to article: SterigenicsGo to article: Owen MumfordGo to article: Are we nearing the end of animal testing in pharma?Go to article: Zenatek Go to article: Barc Lab Go to article: A safer ride: the latest innovation in targeted cancer treatment Go to article: Abiogen PharmaGo to article: MimotopesGo to article: Next issue